GMM Pfaudler Earnings Call Transcript: Key Takeaways

Guidance and delivery
Management target	Revenue 10.0% FY27

Highlights
Revenue growth	10% YoY revenue growth; India business performed strongly at 12%.
Margins	Sequential gross margin compression; targeting 15% EBITDA margin long-term.
Order book	Record backlog up 34%; order intake rose 20% to ₹3,714 Crores.
Demand visibility	Strong backlog visibility; pharma remains robust while chemicals are slowing.
Management confidence	Cautious; reluctant to provide bullish guidance due to global macro uncertainties.

Growth

India grew 12% in revenue and 24% in EBITDA; however, consolidated gross margins dropped to 55.4%.

Targeting 15% consolidated EBITDA margin over next 3 years; double-digit revenue growth guided.

High interest costs from Luxembourg entities and potential order delays due to Middle East/Geopolitical tensions.

Guided for strong backlog visibility → delivered 34% increase in opening backlog (= BEAT)
Guided for India revenue growth → delivered 12% YoY growth (= BEAT)
Guided for strong order intake → delivered 20% YoY increase to ₹3,714 Cr (= BEAT)

Guided for debt reduction → delivered ₹60Cr repayment but high interest costs persist (= PARTIAL)
Guided for cost savings → delivered ₹45Cr annual run-rate from Germany restructuring (= PARTIAL)

Source

Earnings Call Transcript filed with NSE, NSE: GMMPFAUDLR. Summary written with AI assistance from the document.

Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.